SILIQ
Google image searchProduct monograph
Active ingredient
brodalumab, 210 MG/1.5 ML
DIN: 02473623
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: 2 SINGLE USE PREFILLED SYRINGES
Schedule: Prescription / Schedule D
Company: BAUSCH HEALTH, CANADA INC.
Date: 07-JUN-2019
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC12 — BRODALUMAB (ATC/DDD)
